Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Task Force to Be Created for Reform of Pharmaceutical Regulations
March 14, 2011
- Restriction on Use of Multiple Drugs in the Elderly Needs Careful Review: Dr Adachi
March 14, 2011
- JPMA Introduces GL for Disclosure of Funds Provided to Healthcare Professionals
March 14, 2011
- Terumo to Launch DuraHeart in April
March 14, 2011
- Zyprexa Applied for Depressive Symptoms Associated with Bipolar Disorders
March 14, 2011
- Terumo's Drug-eluting Stent Recommended for Approval
March 14, 2011
- 14-Day Prescription Limit Will Not Apply to Sonias
March 14, 2011
- 4 Deaths Reported Following Simultaneous Vaccination with Prevnar, ActHIB, DPT Vaccine
March 14, 2011
- Banzel Oral Suspension Approved in the US: Eisai
March 14, 2011
- Tumor Lysis Syndrome Added as Serious ADR Associated with Imatinib, Nilotinib
March 14, 2011
- Eisai to Shift Priority to East Asia
March 14, 2011
- Daiichi Sankyo to Acquire Plexxikon
March 14, 2011
- Develop Biomarkers with Therapeutic Agents: Dr Suzuki of Roche Pharma Japan
March 7, 2011
- Azilsartan Approved by FDA: Takeda
March 7, 2011
- BMKK Aims at Top-20 Position in Japan by 2015
March 7, 2011
- Novartis to Expand SOV for Equa through Comarketing with Sanofi-aventis
March 7, 2011
- JPO's Decision on Actos Patent Infringement Case Expected Soon
March 7, 2011
- FUJIFILM to Acquire 2 Contract Biopharmaceuticals Manufacturers from US Merck
March 7, 2011
- Aricept's Patent Period Extension Upheld by IP High Court
March 7, 2011
- Top 4 Products Neck and Neck in Global Market for Antibody Drugs
March 7, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…